Progress on the treatment of cardiovascular disease with bone marrow stem cells

Abstract

Abstract: Bone marrow stem cells are a population of multipotent cells,including two types of hematopoietic stem cells and mesenchymal stem cells,which are widely exist in bone marrow tissue.With the capacity of self-renewal and multiple differentiation,under certain conditions,bone marrow stem cells can be induced to differentiate into a variety of cells including myocardial cells and be used as ideal seed cells for tissue and organ damage caused by aging and disease, especially for the clinical treatment of cardiovascular disease,such as myocardial infarction,ischemic heart failure,intractable angina,dilated cardiomyopathy and so on.The progress on the bone marrow stem cells for the treatment of cardiovascular disease were reviewed in this paper.

Key words: bone marrow stem cell, myocardial infarction, ischemic heart failure, intractable angina, dilated cardiomyopathy

CLC Number:

R541.4

ZHAO Chun-mei, WANG An-cai, WANG De-guo. Progress on the treatment of cardiovascular disease with bone marrow stem cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 948-952.

References 27

[1]	Orlic D,Kajstura J,Chimenti S,et al.Bone marrow cells regenerate infarcted myocardium[J].Nature,2001,410:701-705.
[2]	Murry CE,Soonpaa MH,Reinecke H,et al.Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts[J]. Nature, 2004,428:664-668.
[3]	Leistner DM, Fischer-Rasokat U,Honold J,et al.Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI):Final 5-year results suggest long-term safety and efficacy[J].Clin Res Cardiol, 2011,100(10):925-934.
	Mansour S,Roy DC,Bouchard V,et al.One-Year Safety analysis of the compare-ami trial: comparison of intracoronary injection of cd133 bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction[J].Bone Marrow Res,2011,2011:385124.
[5]	Roncalli J,Mouquet F,Piot C,et al.Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction:Results of the randomized multicenter BONAMI trial[J].Eur Heart J,2011,32(14):1748-1757.
[6]	Benedek I,Bucur O,Benedek T.Intracoronary infusion of mononuclear bone marrow-derived stem cells is associated with a lower plaque burden after four years[J].J Atheroscler Thromb, 2014,21(3):217-229.
[7]	Beitnes JO,Hopp E,Lunde K,et al.Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction:The ASTAMI randomised, controlled study[J].Heart,2009,95(24):1983-1989.
[8]	Beitnes JO,Gjesdal O,Lunde K,et al.Left ventricular systolic and diastolic function improve after acute myocardial infarction treated with acute percutaneous coronary intervention, but are not influenced by intracoronary injection of autologous mononuclear bone marrow cells:A 3 year serial echocardiographic sub-study of the randomized-controlled ASTAMI study[J].Eur J Echocardiogr,2011,12(2):98-106.
[9]	Rodrigo SF,Van Ramshorst J,Hoogslag GE,et al.Intramyocardial Injection of Autologous Bone Marrow-Derived Ex Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients is Feasible and Safe up to 5 Years of Follow-up[J].J Cardiovasc Transl Res,2013,6(5):816-825.
[10]	Gao LR,Pei XT,Ding QA,et al.A critical challenge: Dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction[J].Int J Cardiol,2013,168(4):3191-3199.
[11]	Wöhrle J,Von Scheidt F,Schauwecker P,et al.Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial[J].Clin Res Cardiol,2013,102(10):765-770.
[12]	Traverse JH,Henry TD,Ellis SG,et al.Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function:the LateTIME randomized trial[J].JAMA,2011,306(19):2110-2119.
[13]	Sürder D,Manka R,Lo Cicero V,et al.Intracoronary injection of bone marrow-derived mononuclear cells early or Late after acute myocardial infarction:effects on global left ventricular function[J].Circulation,2013,127(19):1968-1979.
[14]	Lu M,Liu S,Zheng Z,et al.A pilot trial of autologous bone marrow mononuclear cell transplantation through grafting artery: A sub-study focused on segmental left ventricular function recovery and scar reduction[J].Int J Cardiol,2013,168(3):2221-2227.
[15]	Ben-Mordechai T,Holbova R,Landa-Rouben N,et al.Macrophage Subpopulations are Essential for Infarct Repair with and without Stem Cell Therapy[J].J Am Coll Cardiol, 2013,62(20):1890-1901.
[16]	Duran JM,Makarewich CA,Sharp TE,et al.Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms[J].Circ Res,2013,113(5):539-552.
[17]	Perin EC,Silva GV,Henry TD,et al.A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF)[J].Am Heart J,2011,161(6):1078-1087.
[18]	Perin EC,Willerson JT,Pepine CJ,et al.Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure:the FOCUS-CCTRN trial[J].JAMA,2012,307(16):1717-1726.
[19]	Fisher SA,Dorée C,Brunskill SJ,et al.Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis[J].PLoS One,2013,8(6):646-669.
[20]	de la Fuente LM,Stertzer SH,Argentieri J,et al.Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label,nonrandomized,single-center pilot study (the TABMMI study)[J].Am Heart J,2007,154(79):71-77.
[21]	de la Fuente LM,Stertzer SH,Argentieri J,et al.Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase I safety study (the TABMMI study)[J].EuroIntervention,2011,7(7):805-812.
[22]	Hare JM,Fishman JE,Gerstenblith G,et al.Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy:the POSEIDON randomized trial[J].JAMA,2012,308(22):2369-2379.
[23]	Hu S, Liu S,Zheng Z,et al.Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure:a single-center,randomized,double-blind,placebo-controlled clinical trial[J].J Am Coll Cardiol,2011,57(24):2409-2415.
[24]	Losordo DW,Schatz RA,White CJ,et al.Intramyocardial transplantation of autologous C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml1-1009-2501-19-8-948"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>34</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula> stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial[J].Circulation,2007,115(25):3165-3172.
[25]	Losordo DW,Henry TD,Davidson C,et al.Intramyocardial autologous cd34+ cell therapy for refractory angina[J].Circ Res,2011,109(4):428-436.
[26]	Wang S,Cui J,Peng W,et al.Intracoronary autologous C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml2-1009-2501-19-8-948"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>34</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula> stem cell therapy for intractable angina[J].Cardiology,2010,117(2):140-147.
[27]	Seth S,Bhargava B,Narang R,et al.The ABCD(Autologous Bone marrow Cells in Dilated Cardiomyopathy) trial a long-term follow-up study[J].J Am Coll Cardiol, 2010,55(15):1643-1644.

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	QIAN Jin, WANG Fengyan. Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
[3]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[4]	CHEN Xi, LI Yongjun. Effects of Chinese patent medicine for activating blood circulation on cardiac repair after myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 680-688.
[5]	YANG Yongkang, LI Jing, RAO Tingcai, ZHANG Junyan. Hyperoside ameliorates the injury of heart and thoracic aorta in mice with myocardial infarction by regulating autophagy pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 601-608.
[6]	ZHAO Wei, WU Youyang, LIN Cong, HUANG Shiwei, CHEN Hao, JIANG Wenbing. Effects of pterostilbene on myocardial function, myocardial fibrosis and inflammatory response in rats with acute myocardial infarction and on Notch1/eIF3a signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 498-504.
[7]	FU Xiaomei, HUO Ran, DENG Sai, LIN Chaojin, FAN Jinghao, WANG Ping, LI Songpei, QIN Aiping, ZOU Minghui, YU Xiyong. Exosomes derived from LPS-stimulated bone marrow mesenchymal stem cell improve myocardial inflammation and fibrosis after myocardial infarction in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 841-851.
[8]	PU Chun, TAO Qingsong, ZHU Xiang, QIN Mingming, WU Qiwen, FENG Gang. Value of three cardiac markers in the early diagnosis of acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 82-86.
[9]	WEI You-quan, CAO Heng. Effects of recombinant human insulin-like growth factor-Ι on the expression of matrix metalloproteinases and interstitial degradation of myocardial infarction rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 866-871.
[10]	LI Yi-min, HUANG Jin, LU Zhi-ping, LI Xiang-yu, HE Sheng-hu. Effects of tirofiban on the level of platelet microparticles(PMPs) in patients with acute ST-segment elevation myocardial infarction undergoing emergency interventional treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1403-1406.
[11]	ZHOU Yong, HUANG Song-qun, XU Fei. Efficacy on slow bleeding and safety of using tirofiban before and during emergency PCI in patients with acute ST-segment elevation myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1268-1271.
[12]	ZHU Lin-lin, XIE Xiang-rong, ZHANG Juan, SHAN Shou-jie , CHEN Shao-liang. Long-term efficacy of intracoronary stem cells transplantation in patients with acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 674-679.
[13]	LI Shu, ZHANG Gen-bao, HONG Yun, LU Xiao-hua. Study on mechanisms of Agkistrodon halyx pallas venom PCA to improve heart function in rats with acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 141-146.
[14]	ZHU Gang-yan, XU Hong-xin, TIAN Yi-hao, MA Hong-mei, TANG Shi-qi, WANG Fu-liang, WU Song-lin. Ameliorative effects of trimetazidine on bone marrow mesenchymal stem cells viability through Bcl-2 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 729-735.
[15]	DENG Shao-xiong, GUO Nan-ou, ZHENG-Yuan, HUANG Wen-sen. Effect and clinical significance of tirofiban on serum matrix metalloproteinase 9 after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction and diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 807-811.